
The Ovagen Analysis is a targeted laboratory test designed to confirm the identity, determine the amount, and assess the peptide purity of Ovagen in lyophilised vials and raw active pharmaceutical ingredient (API) powders.
For lyophilised samples, results are reported in milligrams per vial together with peptide purity. Raw API powders can be evaluated using purity in % (m/m) together with peptide purity.
Ovagen corresponds to the synthetic tripeptide Glu-Asp-Leu (EDL). This short peptide has been investigated primarily in experimental studies focused on kidney function, renal cell renewal, and responses to kidney injury.
Available scientific evidence is mainly based on laboratory and preclinical studies.
Important Notice
- This analysis is specifically intended for Ovagen with the Glu-Asp-Leu (EDL) sequence. It does not automatically screen the sample for other peptides, related compounds, degradation products, contaminants, or undeclared substances.
- For lyophilised samples, one whole unopened vial containing lyophilisate is required.
- Raw API powder should be supplied as at least 30 mg in a sealed glass vial to protect the sample from moisture.
- The alternative result format for raw API powders includes both purity in % (m/m) and peptide purity.
The following optional laboratory services are available:
